Read Larry Connors' blog – Short Term Trading Strategies
Genzyme Corp., the world's third-largest biotechnology company, has dismantled equipment and scrubbed surfaces with spore-killing bleach in an effort to kill the Vesivirus 2117 strain, which also showed up at the plant in November, it said.
The 28-year-old company, whose products are available in nearly 90 countries, also found the virus, which can affect the growth of cells used to make the treatments, at its Geel, Belgium, plant in September.
In Boston, it soon plans to wheel in "vaporizers" that will disperse clouds of vaporized hydrogen peroxide throughout the 185,000-square-foot production area, The Boston Globe reported.
"It kills all known living things," Mark Bamforth, Genzyme's senior vice president for corporate operations, told the newspaper.
The U.S. Food and Drug Administration, which is investigating, has not determined the contamination's root cause.
The temporary production standstill comes when inventories for the halted drugs, Cerezyme and Fabrazyme, "are not sufficient to meet projected global demand," Genzyme said in a statement.
Cerezyme treats Gaucher disease and Fabrazyme treats Fabry disease. Both conditions cause waste to build up in the body, swelling organs.
The drugs, taken intravenously about every other week, cost about $200,000 a year per patient, the Globe said.
Because of the temporary shutdown, drug doses to about 8,000 patients are being rationed, Genzyme said.
It did not say if it planned to recall any drugs already on the market.
The company said it was working with physicians, patients and regulators "to minimize the impact of this constraint."
www.upi.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
